Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination

Kahn, Benjamin; Apostolidis, Sokratis A.; Bhatt, Vatsal; Greenplate, Allison R.; Kallish, Staci; LaCava, Anthony; Lucas, Alfredo; Meyer, Nuala J.; Negoianu, Dan; Ogdie, Alexis; Shashaty, Michael G. S.; Takach, Patricia; Zuroff, Leah; Wherry, E. John; Anesi, George L

doi:10.1097/cce.0000000000000578

Cited by 15 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kahn et al [ 27 ] presented the singular case of a 20-years-old male who developed multisystem inflammation and organ dysfunction beginning a few hours after the first dose of Pfizer COVID-19 vaccine. His clinical condition worsened in the next 48 h, with systemic inflammation, hematuria, progressive acute kidney failure (which required hemodialysis), and profound SSNHL.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Audiovestibular Disorders after COVID-19 Vaccine: Is There an Association?

et al. 2022

View full text Add to dashboard Cite

The SARS-CoV-2 vaccination campaign is probably one of the most historic public hygiene measures in modern medicine. The drama of the pandemic has forced the scientific community to accelerate the development and commercialization of vaccines, thereby enhancing the phases of active surveillance. Among the adverse events following immunization (AEFI) reported, those of an audiovestibular interest, such as sudden sensorineural hearing loss (SSNHL), tinnitus, dizziness, and vertigo, constitute a very small percentage. There are many plausible etiological hypotheses, and scientific research needs to pay more attention to the correct collection of data, which up until now have often been inadequate and fragmented, on which to base future studies. SSNHL, new onset tinnitus, vertigo, and dizziness require a prompt evaluation, while the proposed treatment is the same as it is for events unrelated to vaccination. These are uncommon adverse events, and the risk rates for these diseases have not increased in conjunction with the COVID-19 vaccinations, therefore there is no justification of any hesitation towards the vaccination campaign.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Among the selected papers, seven were related to SSNHL following COVID-19 immunization, mainly with associated tinnitus [ 21 , 22 , 23 , 24 , 25 , 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Audiovestibular Disorders after COVID-19 Vaccine: Is There an Association?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There were also patients who had prior biopsy-proven IgAN, who developed gross hematuria after their second dose of the BNT162b2 vaccine, without a preceding COVID-19 infection, and patients who had minimal change in disease and AKI following BNT162b2 vaccination ( D’agati et al, 2021 ; Plasse et al, 2021 ). After receiving the first dose of the BNT162b2 COVID-19 vaccine, a 20-year-old male college student developed AKI that required hemodialysis ( Kahn et al, 2021 ). According to Luo et al’s statement in an epidemiological study, mRNA vaccinations (such as BioNTech and mRNA-1273) were more frequently linked to AKI than adenovirus vaccines (such as Ad26.COV2.S), which was consistent with our results ( Luo et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS

Yan¹,

Zhao²,

Li³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background and purpose: Serious adverse events following immunization (AEFI) associated with the COVID-19 vaccines, including BNT162b2 (Pfizer-BioNTech), Ad26.COV2.S (Janssen), and mRNA-1273 (Moderna), have not yet been fully investigated. This study was designed to evaluate the serious AEFI associated with these three vaccines.Methods: A disproportionality study was performed to analyze data acquired from the Vaccine Adverse Event-Reporting System (VAERS) between 1 January 2010 and 30 April 2021. The reporting odds ratio (ROR) method was used to identify the association between the COVID-19 vaccines BNT162b2, Ad26.COV2.S, and mRNA-1273 and each adverse event reported. Moreover, the ratio of the ROR value to the 95% CI span was applied to improve the credibility of the ROR. The median values of time from vaccination to onset (TTO) for the three vaccines were analyzed.Results: Compared with BNT162b2 and mRNA-1273, Ad26.COV2.S vaccination was associated with a lower death frequency (p < 0.05). Ad26.COV2.S vaccination was associated with a lower birth defect and emergency room visit frequency than BNT162b2 (p < 0.05). There were 6,605, 830, and 2,292 vaccine recipients who suffered from COVID-19-related symptoms after vaccination with BNT162b2, Ad26.COV2.S, and mRNA-1273, respectively, including people who were infected by COVID-19, demonstrated a positive SARS-CoV-2 test, and were asymptomatic. Serious AEFI, including thromboembolism, hemorrhage, thrombocytopenia, cardiac arrhythmia, hypertension, and hepatotoxicity, were associated with all three vaccines. Cardiac failure and acute renal impairment events were associated with BNT162b2 and mRNA-1273, while seizure events were associated with BNT162b2 and Ad26.COV2.S. The median values of TTO associated with the three vaccinations were similar.Conclusion: These findings may be useful for health workers and the general public prior to inoculation, especially for patients with underlying diseases; however, the risk/benefit profile of these vaccines remains unchanged. The exact mechanism of SARS-CoV-2 vaccine-induced AEFI remains unknown, and further studies are required to explore these phenomena.

show abstract

“…13 , 14 Given the patient's lack of comorbid conditions and unrevealing, extensive workup for his hyper-inflammatory state by a multidisciplinary medical team, we strongly suspect this patient to have a rare case of multisystem inflammatory syndrome-vaccine (MIS-V), as coined by Nune et al 14 Furthermore, despite clinical and laboratory improvements, he continued to have elevated levels of CXCL9, a chemokine specifically induced by IFN-gamma, suggestive of an interferonopathy that predisposes him to massive inflammatory responses. 15 , 16 …”

Section: Discussionmentioning

confidence: 99%